



**SHATTUCK**  
LABS

NEWS RELEASE

# Shattuck Labs Announces Participation in Upcoming March Investor Conferences

2026-02-25

AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

## Conference Details

### TD Cowen 46<sup>th</sup> Annual Health Care Conference

**Format:** Corporate presentation and one-on-one meetings  
**Presenter:** Taylor Schreiber, M.D., Ph.D., Chief Executive Officer  
**Presentation Date:** March 2, 2026  
**Time:** 9:10 AM ET  
**Location:** Boston, MA  
**Webcast link:** [HERE](#)

### Leerink Partners 2026 Global Health Care Conference

**Format:** One-on-one investor meetings  
**Participant:** Taylor Schreiber, M.D., Ph.D., Chief Executive Officer  
**Dates:** March 10-11, 2026  
**Location:** Miami, FL

Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company's website at [www.shattucklabs.com](http://www.shattucklabs.com). Replay webcasts will be available for approximately 30 days following the live presentations.

## About SL-325

SL-325 is a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a

complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck's preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 is a fully Fc-silenced humanized immunoglobulin G monoclonal antibody with a favorable safety profile in non-human primates, currently being evaluated in a Phase 1 clinical trial.

**About Shattuck Labs, Inc.**

Shattuck Labs, Inc. (Nasdaq: STTK), a clinical-stage biotechnology company, is pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. The Company's expertise in protein engineering and the development of novel TNF receptor therapeutics comes together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

**Investor & Media Contact:**

Andrew R. Neill  
Chief Financial Officer  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

Source: Shattuck Labs, Inc.